KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Assets (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Current Assets data on record, last reported at $281.4 million in Q3 2025.

  • For Q3 2025, Current Assets fell 1.79% year-over-year to $281.4 million; the TTM value through Sep 2025 reached $281.4 million, down 1.79%, while the annual FY2024 figure was $261.3 million, 20.99% down from the prior year.
  • Current Assets reached $281.4 million in Q3 2025 per NKTR's latest filing, up from $186.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.1 billion in Q1 2021 and bottomed at $186.6 million in Q2 2025.
  • Average Current Assets over 5 years is $531.3 million, with a median of $445.0 million recorded in 2023.
  • Peak YoY movement for Current Assets: tumbled 39.43% in 2023, then decreased 1.79% in 2025.
  • A 5-year view of Current Assets shows it stood at $795.6 million in 2021, then plummeted by 31.37% to $546.0 million in 2022, then crashed by 39.43% to $330.7 million in 2023, then decreased by 20.99% to $261.3 million in 2024, then increased by 7.68% to $281.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $281.4 million in Q3 2025, $186.6 million in Q2 2025, and $229.9 million in Q1 2025.